4-hydroxy-n-desmethyltamoxifen and Bipolar-Disorder

4-hydroxy-n-desmethyltamoxifen has been researched along with Bipolar-Disorder* in 4 studies

Trials

1 trial(s) available for 4-hydroxy-n-desmethyltamoxifen and Bipolar-Disorder

ArticleYear
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.
    Bipolar disorders, 2021, Volume: 23, Issue:6

    Endoxifen is a protein kinase C inhibitor. The objective of the present phase III study was to demonstrate the safety and efficacy of endoxifen in treating bipolar I disorder (BPD I) patients.. A multicenter, double-blind, active-controlled study was conducted using a daily dose of 8 mg endoxifen compared to 1000 mg divalproex, the current standard treatment, in patients with BPD I acute manic episodes with/without mixed features. The primary endpoint of our study was the mean change in total Young Mania Rating Scale (YMRS) score at day 21.. Endoxifen (n = 116) significantly (p < 0.0001) reduced total YMRS score (from 33.1 to 17.8. A significant (p < 0.001) improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) score was observed for endoxifen (4.8 to 2.5). Early time to remission of the disease was observed with endoxifen compared to divalproex. None of the patients required rescue medication and there was no drug-associated withdrawals. Changes in Clinical Global Impressions-Bipolar Disorder and Clinical Global Impression-Severity of Illness scores showed that treatment with endoxifen was well-tolerated.. Endoxifen at a low daily dose of 8 mg was as efficacious and safe in patients with BPD I acute manic episodes with/without mixed features.

    Topics: Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Humans; Mania; Protein Kinase C; Psychiatric Status Rating Scales; Tamoxifen; Treatment Outcome

2021

Other Studies

3 other study(ies) available for 4-hydroxy-n-desmethyltamoxifen and Bipolar-Disorder

ArticleYear
Reply to Ghosh et al
    Bipolar disorders, 2022, Volume: 24, Issue:1

    Topics: Bipolar Disorder; Humans; Mania; Protein Kinase C; Tamoxifen

2022
Endoxifen: A new hope for Bipolar Disorder.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71, Issue:11

    Topics: Bipolar Disorder; Breast Neoplasms; Female; Humans; Tamoxifen

2021
Efficacy of endoxifen, a protein kinase C inhibitor for acute and mixed mania: Some concerns worth considering.
    Bipolar disorders, 2021, Volume: 23, Issue:6

    Topics: Bipolar Disorder; Humans; Mania; Protein Kinase C; Tamoxifen

2021